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Paced Left Ventricular QRS Width and ECG Parameters
Predict Outcomes After Cardiac Resynchronization Therapy
PROSPECT-ECG Substudy
Jeff M. Hsing, MS, MD; Kimberly A. Selzman, MD, MPH; Christophe Leclercq, MD, PhD;
Luis A. Pires, MD; Michael G. McLaughlin, MD; Scott E. McRae, MS;
Brett J. Peterson, BS; Peter J. Zimetbaum, MD
Background—For patients with symptomatic New York Heart Association class III or IV, ejection fraction 35%, and
QRS 130 ms, cardiac resynchronization therapy (CRT) has become an established treatment option. However, use of
these implant criteria fails to result in clinical or echocardiographic improvement in 30% to 45% of CRT patients.
Methods and Results—The Predictors of Response to CRT (PROSPECT)-ECG is a substudy of the prospective observational
PROSPECT trial. ECGs collected before, during, and after CRT implantation were analyzed. Primary outcomes were
improvement in clinical composite score (CCS) and reduction of left ventricular end systolic volume (LVESV) of 15% after
6 months. Age, sex, cause of cardiomyopathy, myocardial infarction location, right ventricular function, mitral regurgitation,
preimplantation QRS width, preimplantation PR interval, preimplantation right ventricular–paced QRS width, preimplantation
axis categories, LV-paced QRS width, postimplantation axis categories, difference between biventricular (Bi-V) pacing and
preimplantation QRS width, and QRS bundle branch morphological features were analyzed univariably in logistic regression
models to predict outcomes. All significant predictors (0.1), age, and sex were used for multivariable analyses.
Cardiomyopathy cause interaction and subanalyses were also performed. In multivariable analyses, only QRS left bundle
branch morphological features predicted both CCS (odds ratio [OR]2.46, P0.02) and LVESV (OR2.89, P0.048)
response. The difference between Bi-V and preimplantation QRS width predicted CCS improvement (OR0.89, P0.04).
LV-paced QRS width predicted LVESV reduction (OR0.86, P0.01). Specifically, an LV-paced QRS width of 200 ms
was predictive of nonischemic LVESV reduction (OR5.12, P0.01).
Conclusions—Baseline left bundle branch QRS morphological features, LV-paced QRS width, and the difference between
Bi-V and preimplantation QRS width can predict positive outcomes after CRT and may represent a novel intraprocedural
method to optimize coronary sinus lead placement.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00253357.
(Circ Arrhythm Electrophysiol. 2011;4:851-857.)
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Cardiac resynchronization therapy (CRT) has become awell-established treatment option for patients with de-
pressed left ventricular function, congestive heart failure, and
a prolonged QRS width. Between 30% and 45% of patients
who undergo CRT fail to demonstrate clinical benefit or echo-
cardiographic evidence of improved left ventricular function.1–4
The Predictors of Response to CRT (PROSPECT) was a
prospective, observational, multicenter clinical trial designed
to test the predictive value of a comprehensive set of
echocardiographic predictors of dyssynchrony to identify
response to CRT.5 In addition, this trial also evaluated a series
of electrocardiographic parameters to determine their useful-
ness in predicting outcomes after CRT. We present the results
of an analysis of preprocedural and intraprocedural implan-
tation electrocardiographic Predictors of Response to CRT
(PROSPECT-ECG), a substudy of PROSPECT.
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Methods
Patients and Study Protocol
Patients included in this analysis were from the PROSPECT trial.5
Enrollment criteria were based on standard guidelines, specifically left
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ventricular ejection fraction 35%, QRS width 130 ms, New York
Heart Association functional class III or IV, despite optimal medical
therapy, including angiotensin-converting enzyme inhibitor or angioten-
sin receptor blocker for at least 1 month and -blocker started at least 3
months before enrollment. Patients were enrolled across 53 centers in
the United States, Europe, and Hong Kong from March 2004 to
December 2005. A total of 498 patients were enrolled, with 31 early
exits and 41 having QRS 130 ms, leaving 426 for the final study
group. There were 2 separate primary outcomes: heart failure clinical
composite score (CCS) and left ventricular end systolic volume
(LVESV). All 426 patients had complete CCSs. There were 286 patients
who had baseline and 6-month echocardiograms for paired LVESV
measurements. All centers collected baseline ECG data before CRT
implantation. At implantation, ECGs of right ventricular (RV)– and
LV-only pacing and biventricular (Bi-V) pacing were collected. A
Medtronic market-released CRT device, with or without implantable
cardioverter-defibrillator functionality, was used in the study.
Electrocardiographic Core Laboratories
All recorded ECGs were reviewed at the ECG core laboratory,
Harvard Clinical Research Institute, for analysis. All centers col-
lected baseline ECG data before the implantation procedure for
analysis, including preimplantation QRS width, PR interval, QRS
axis, and QRS bundle branch morphological features. During device
implantation, the ECG data collected for analysis included RV-paced
QRS width, LV-paced QRS width, Bi-V–paced QRS axis, and
Bi-V–paced QRS width. The difference between Bi-V and preim-
plantation QRS width was calculated for analysis. ECG measure-
ments were made using any lead to obtain the largest value. QRS
bundle branch morphological features were assessed using lead V1.
Definition of Response to CRT
A response to CRT in the PROSPECT trial was determined through
the use of 2 separately analyzed primary outcomes at 6 months: heart
failure CCS and relative change in LVESV. The CCS describes
patients, regardless of vital status, at 6 months and combines both
objective and subjective measures of clinical status, including
all-cause mortality, New York Heart Association class, heart failure
hospitalization, and patient global assessment.6 A patient’s CCS was
classified as worsened, improved, or unchanged. A positive response
to CRT was defined as a CCS designation of “improved” and/or a
reduction in LVESV of 15% at 6 months compared with baseline.
Statistical Analysis
The analysis included 14 variables that were used in logistic regression
models to assess their association with response to CRT. These included
age, sex, cause of cardiomyopathy, myocardial infarction location, RV
function, mitral regurgitation, preimplantation QRS width, preimplan-
tation PR interval, preimplantation RV-paced QRS width, preimplanta-
tion and postimplantation axis categories, LV-paced QRS width, a
variable defined for the difference between Bi-V and preimplantation
QRS width, and QRS bundle branch morphological features. Preim-
plantation QRS width, LV-paced QRS width, and the difference
between Bi-V and preimplantation QRS width were all defined in
increments of 10 ms. QRS bundle branch morphological features were
assessed using lead V1 and were categorized into left bundle branch
block (LBBB), right bundle branch block (RBBB), or indeterminate. A
QRS morphological comparison was made between LBBB and RBBB.
A univariable logistic regression model was defined for each variable
versus the CCS response and the LVESV response. Only those subjects
with available data were used in the models. P0.10 was used to select
variables for multivariable analysis. Multivariable logistic regression
models were then defined for each response variable, with the statisti-
cally significant variables from the univariable models used as covari-
ates. Age and sex were also included in all multivariable models as
covariates. Covariates that were significant in the final multivariable
model, with P0.05, were further analyzed for interactions between the
covariate and cardiomyopathy cause (ischemic versus nonischemic),
along with the associated subanalyses. Odds ratios (ORs) and associated
95% CIs from the logistic regression models were calculated.
Univariable and multivariable analyses for CCS and LVESV re-
sponses were repeated by replacing preimplantation QRS width with
dichotomized QRS width 150 ms versus 150 ms for comparison
with other previously published CRT trials. The multivariable analyses
were repeated on a dichotomy of postimplantation LV QRS width for
the LVESV response only. The value used as the cut point for the
dichotomy was chosen by looking at a 10-ms interval and selecting one
that had good sensitivity and balancing specificity.
Results
A total of 498 patients were enrolled and 467 patients
completed CRT implantation. CCS was completed in 426
patients, as 41 were removed because of a reduction in the
preimplantation QRS width below the required 130 ms at
implantation. Of the 426 patients, 363 underwent a baseline
echocardiogram; 286 of these patients completed a 6-month
visit with an echocardiogram, allowing assessment of the
LVESV end point (Figure). Of the 426 patients, 84 were CRT
upgrades and 342 were new implants. A total of 413 preim-
plantation ECGs and 376 postimplantation ECGs were avail-
able for analysis. The QRS morphological features on the
ECG were distributed as follows: 87% had LBBB, 10% had
RBBB, and 3% were indeterminate.
Based on the CCS end point, 69% of patients improved, 16%
worsened, and 15% remained unchanged. Based on the LVESV
end point, 56% had 15% reduction, 9% had 15% increase,
and 35% had 15% increase or decrease in LVESV.
Univariable and Multivariable Models
For the univariable models, P0.10 was considered signifi-
cant and the corresponding variable was included in the
multivariable model. The significant predictors in the univari-
able models for CCS response were nonischemic cardiomy-
opathy (OR0.57, P0.01), preimplantation RV-paced QRS
width (OR0.98, P0.10), preimplantation QRS axis cate-
gory (P0.10), difference between Bi-V and preimplantation
QRS width (OR0.87, P0.01), and QRS left bundle branch
morphological features (OR2.47, P0.01) (Table 1). The
significant predictors in the univariable models for LVESV
response were female sex (OR1.72, P0.04), nonischemic
cardiomyopathy (OR0.60, P0.03), RV function
(OR0.40, P0.05), preimplantation PR interval (OR0.99,
P0.01), preimplantation QRS width (OR1.10, P0.08),
LV-paced QRS width (OR0.94, P0.07), the difference
between Bi-V and preimplantation QRS width (OR0.81,
P0.01), and QRS left bundle branch morphological features
(OR3.38, P0.01) (Table 2). The variables that predicted a
significant positive response for both CCS improvement and
LVESV reduction were nonischemic cardiomyopathy, differ-
ence between Bi-V and preimplantation QRS width, and QRS
left bundle branch morphological features.
Variables in the univariable analysis with P0.10, as well
as age and sex, were included in the multivariable model.
Multivariable significant predictors were defined as having a
P0.05. Preimplantation RV-paced QRS width was not used
in multivariable analysis because of the few ECGs available
for analysis. After multivariable analysis, the significant predic-
tors of CCS response were the difference between Bi-V and
preimplantation QRS width (OR0.89, P0.04) and QRS left
bundle branch morphological features (OR2.46, P0.02)
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(Table 1). The significant multivariable predictors for LVESV
response were LV-paced QRS width (OR0.86, P0.01) and
QRS left bundle branch morphological features (OR2.89,
P0.048) (Table 2). The only variable in the multivariable
analysis that predicted a significant positive response for both
CCS improvement and LVESV reduction was QRS left bundle
branch morphological features. After adjusting for other signif-
icant predictors, LBBB patients were more likely than RBBB
patients to have a positive CCS response, with an OR of 2.46,
and an LVESV response, with an OR of 2.89.
Figure. Enrollment and follow-up of
patients in PROSPECT. Reprinted with
permission from PROSPECT.
Table 1. Univariable and Multivariable Analysis for CCS End Point
Explanatory Variables Comparison of Levels
Univariable Multivariable
OR Estimates (95%
Confidence Limits) P Value
OR Estimates (95%
Confidence Limits) P Value
Age (n426) Continuous 1.00 (0.98, 1.02) 0.88 1.00 (0.98, 1.02) 0.98
Sex (n426) Female vs male 1.20 (0.76, 1.91) 0.43 0.89 (0.51, 1.57) 0.70
Cause of cardiomyopathy (n426) Ischemic vs nonischemic 0.57 (0.38, 0.87) 0.01 0.64 (0.38, 1.10) 0.11
MI location (n149) Anterior vs posterior 0.54 (0.11, 2.78) 0.53
Inferior vs posterior 0.42 (0.08, 2.21)
RV function (n371) Moderately/severely
depressed vs normal/mildly
depressed
0.59 (0.27, 1.29) 0.19
Mitral regurgitation (n254) Moderate (20–40%)/severe
(40%) vs none/mild
(20%)
0.72 (0.42, 1.22) 0.22
Preimplantation QRS width (n376) 10-ms Increments 1.06 (0.97, 1.16) 0.21
Preimplantation PR interval (n370) Continuous 1.00 (1.00, 1.01) 0.74
Preimplantation RV- paced QRS width (n32) Continuous 0.98 (0.95, 1.00) 0.10
Preimplantation axis categories (n413) 75 vs 130 2.75 (0.86, 8.77) 0.10 1.31 (0.51, 3.35) 0.34
75–0 vs 130 1.21 (0.54, 2.68) 3.00 (0.62, 14.41)
0–130 vs 130 1.92 (0.81, 4.55) 1.85 (0.69,4.99)
LV-paced QRS width (n307) 10-ms Increments 0.96 (0.91, 1.02) 0.20
Postimplantation axis categories (n376) 75 vs 130 1.52 (0.76, 3.04) 0.34
75–0 vs 130 1.47 (0.80, 2.72)
0–130 vs 130 1.56 (0.81, 3.00)
Difference between Bi-V and preimplantation
QRS width (n334)
10-ms Increments 0.87 (0.79, 0.96) 0.01 0.89 (0.80, 0.99) 0.04
QRS bundle branch morphological features in
lead V1 (n405)
LBBB vs RBBB 2.47 (1.30, 4.68) 0.01 2.46 (1.13, 5.39) 0.02
MI indicates myocardial infarction.
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QRS Width >150 ms
A dichotomized QRS width of 150 ms versus 150 ms was
also examined, in addition to the prespecified preimplantation
QRS width in increments of 10 ms. The dichotomized QRS
width results were similar to the preimplantation incremental
QRS width, in which the univariable analysis was statistically
significant for LVESV (OR0.37, P0.01), but not CCS
response. As was the case with preimplantation incremental
QRS width, the dichotomized QRS width did not reach
statistical significance in the multivariable analysis.
ECG Parameters by Cause
The interactions were analyzed between cause of cardiomyopa-
thy (ischemic versus nonischemic) and the ECG parameters that
were statistically significant for prediction of CCS (difference
between Bi-V and preimplantation QRS width and QRS bundle
branch morphological features) and LVESV response (LV-
paced QRS width and QRS bundle branch block morphological
features). Only QRS bundle branch block morphological fea-
tures for the CCS response showed a significant interaction with
cause of cardiomyopathy (P0.03). QRS bundle branch block
morphological features were a significant predictor of CCS
response for nonischemic cause (OR6.34, P0.01) (Table 3).
LV-paced QRS for the LVESV response did not show any
interaction with cause of cardiomyopathy (Table 4).
LV-Paced QRS
LV-paced QRS width was also examined to determine if a
cutoff threshold width could be identified. A cutoff threshold
of 200 ms gave the best combination of sensitivity (72%) and
specificity (40%) in predicting LVESV response compared
with other thresholds. LV-paced QRS width (200 ms versus
200 ms) was significant for overall LVESV response
(OR2.27, P0.04). The interaction between the dichotomy
of LV-paced QRS width and cardiomyopathy cause was also
significant (P0.04) (Table 5). When the cause of cardiomy-
opathy subgroups were further analyzed, the LV-paced QRS
width was significant for nonischemic cause (OR5.12,
Table 2. Univariable and Multivariable Analysis for LVESV End Point
Explanatory Variables Comparison of Levels
Univariable Multivariable
OR Estimates (95%
Confidence Limits) P Value
OR Estimates (95%
Confidence Limits) P Value
Age (n286) Continuous 1.01 (0.98, 1.03) 0.68 1.02 (0.99, 1.06) 0.18
Sex (n286) Female vs male 1.72 (1.01, 2.91) 0.04 0.97 (0.45, 2.10) 0.94
Cause of cardiomyopathy (n286) Ischemic vs nonischemic 0.60 (0.37, 0.96) 0.03 0.93 (0.46, 1.88) 0.84
MI location (n95) Anterior vs posterior 3.33 (0.28, 39.43) 0.21
Inferior vs posterior 1.67 (0.14, 19.76)
RV function (n277) Moderately/severely depressed
vs normal/mildly depressed
0.40 (0.16, 0.99) 0.05 0.56 (0.17, 1.85) 0.34
Mitral regurgitation (n191) Moderate (20–40%)/
severe (40%) vs
none/mild (20%)
0.68 (0.38, 1.21) 0.19
Preimplantation QRS width (n254) 10-ms Increments 1.10 (0.989, 1.23) 0.08 1.15 (0.94, 1.40) 0.18
Preimplantation PR interval (n251) Continuous 0.99 (0.99, 1.00) 0.01 1.00 (0.99, 1.01) 0.93
Preimplantation RV-paced QRS width (n22) Continuous 0.98 (0.95, 1.01) 0.19
Preimplantation axis categories (n281) 75 vs 130 0.74 (0.22, 2.47) 0.26
75–0 vs 130 1.55 (0.60, 4.04)
0–130 vs 130 1.70 (0.63, 4.61)
LV-paced QRS width (n214) 10-ms Increments 0.94 (0.87, 1.00) 0.07 0.86 (0.77, 0.96) 0.01
Postimplantation axis categories (n251) 75 vs 130 0.61 (0.29, 1.26) 0.25
75–0 vs 130 1.59 (0.75, 3.36)
0–130 vs 130 0.95 (0.48, 1.89)
Difference between Bi-V and preimplantation
QRS width (n223)
10-ms Increments 0.81 (0.71, 0.92) 0.01 0.90 (0.74, 1.09) 0.27
QRS bundle branch morphological features
in lead V1 (n273)
LBBB vs RBBB 3.38 (1.53, 7.46) 0.01 2.89 (1.01, 8.27) 0.048
MI indicates myocardial infarction.
Table 3. Significant Multivariable Parameters of CCS
Response by Cause of Cardiomyopathy
Explanatory
Variable
Cause of
Cardiomyopathy Statistic
Response
(95% CI) CCS
P Value of
Interaction
Difference
between
Bi-V and
preimplantation
QRS width
(10-ms
increments)
Ischemic* OR 0.91 (0.79–1.04) 0.65
P value Not tested
Nonischemic* OR 0.86 (0.72–1.03)
P value Not tested
QRS bundle
branch
morphological
features in
lead V1 (LBBB
vs RBBB)
Ischemic OR 1.33 (0.49–3.61) 0.03
P value 0.57
Nonischemic OR 6.34 (1.64–24.46)
P value 0.01
*Subgroup P values were not calculated when the test for interaction was
not significant.
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P0.01), but not for ischemic cause (OR1.35, P0.58).
The LV-paced QRS width using the threshold of 200 ms as a
cutoff was not significant for CCS response (data not shown).
Discussion
To our knowledge, the PROSPECT trial was the first large
multicenter prospective trial of noninvasive predictors of re-
sponse to CRT. In that study, no echocardiographic measure of
dyssynchrony accurately identified patients who would respond
to CRT in a multicenter setting.5 The current analysis represents
the PROSPECT-ECG substudy, which evaluated electrocardio-
graphic measurements, including a novel LV-paced QRS width
to identify CRT responders and to potentially use ECG mea-
surements to guide placement of the CS lead.
The benefit of CRT in RBBB or non-LBBB is unclear. Only
1 study7 has shown a benefit for CRT in patients with RBBB. A
later pooled analysis using both the MIRACLE and Contak CD
studies demonstrated improvement in only New York Heart
Association functional class in patients with baseline RBBB.8
More recent single-center analyses9,10 showed a greater CRT
response with LBBB compared with RBBB and intraventricular
conduction delay. The multicenter MADIT-CRT subanalysis
also found a greater response with LBBB compared with
non-LBBB.11 In the PROSPECT-ECG analysis, QRS morpho-
logical features significantly predicted CRT response. Patients
with baseline LBBB were more likely to respond than patients
with baseline RBBB morphological features. In addition, QRS
morphological features were the only ECG parameter that
predicted both CCS (OR2.46) and LVESV response
(OR2.89) in the multivariable analysis. When further analyzed
by cause of cardiomyopathy, QRS bundle branch morphological
features were only significant for CCS response in patients with
nonischemic cardiomyopathy (OR6.34, P0.01).
Previous studies using preimplantation QRS width to predict
CRT response have yielded conflicting results. Early CRT
studies12,13 showed that an increased preimplantation QRS width
predicted short-term hemodynamic improvement. However,
subsequent long-term follow-up in large CRT clinical trials
found that preimplantation QRS width was a poor predictor of
clinical CRT response.14 In the RethinQ trial,15 patients with a
narrow QRS width and evidence of mechanical dyssynchrony
did not benefit from resynchronization. In that study, subgroup
analysis demonstrated that patients with a QRS width 120 ms
had a much higher response rate than patients with a QRS width
120 ms. A previously reported PROSPECT subanalysis ex-
amined characteristics associated with good and poor response.16
Subjects were classified as a superresponder if they had a
decrease in LVESV 30%, as a responder if they had a decrease
in LVESV of 15% to 29%, as a nonresponder if they had a
decrease in LVESV of 0% to 14%, and as a negative responder
if they had an increase in LVESV and a combination of clinical
and echocardiographic deterioration. In that analysis, preimplan-
tation QRS width was statistically significant between the 4
LVESV groups (P0.03) and when comparing superresponders
with negative responders (P0.039).16 However, preimplanta-
tion QRS width was not significant when comparing the com-
bined clinical and echocardiographic end points (P0.18). A
prespecified MADIT-CRT subanalysis found QRS width 150
ms to be significant for reduction in death and nonfatal heart
failure.17 In this PROSPECT-ECG, preimplantation incremental
QRS width was a predictor of LVESV response in univariable,
but not multivariable, analysis. Similarly, dichotomized QRS
width 150 ms conferred a greater LVESV response than 150
ms in univariable analysis but was a poor predictor of response
after multivariable analysis.
Prediction of CRT response in association with a narrow-
ing of the QRS width with Bi-V pacing has also proved to be
an inconsistent finding in clinical trials.18–20 However, wid-
ening of the QRS after CRT device implantation has been an
independent predictor of mortality or progression to heart
transplantation.21 To our knowledge, there is only 1 prospec-
tive study19 that attempted to minimize the QRS width during
CRT implantation and resulted in a 73% response rate. In that
study, the LV lead was positioned in the standard lateral or
posterolateral vein and the RV lead was positioned in the RV
outflow tract, septum, anterior wall, or apex to minimize QRS
width. In PROSPECT-ECG, we found that the difference
between Bi-V and preimplantation QRS width was predictive
for the CCS end point, with an OR of 0.89 (P0.04).
Previous studies22–24 have suggested a better CRT response
in patients with nonischemic compared with ischemic cause of
cardiomyopathy. It is generally accepted that there is a greater
amount of focal and diffuse scar associated with infarct-related
cardiomyopathy compared with nonischemic cardiomyopa-
thy.25,26 Also, scar at the site of pacing and total scar burden
decrease the response to CRT because dead tissue is less likely
to contract, even with pacing.25–29 In PROSPECT-ECG, nonis-
Table 4. Significant Multivariable Parameters of LVESV
Response by Cause of Cardiomyopathy
Explanatory
Variable
Cause of
Cardiomyopathy* Statistic
Response
(95% CI) LVESV
P Value of
Interaction
LV-paced
QRS width
(10-ms
increments)
Ischemic OR 0.87 (0.74–1.03) 0.17
P value Not tested
Nonischemic OR 0.80 (0.67–0.96)
P value Not tested
QRS bundle
branch
morphological
features in
lead V1
(LBBB vs
RBBB)
Ischemic OR 2.39 (0.61–9.35) 0.74
P value Not tested
Nonischemic OR 3.40 (0.57–20.20)
P value Not tested
*Subgroup P values were not calculated when the test for interaction was
not significant.
Table 5. Summary of LVESV Response Using Dichotomized
LV-Paced QRS Width by Cause of Cardiomyopathy
Explanatory
Variable
Cause of
Cardiomyopathy Statistic
Response
(95% CI)
P Value of
Interaction
LV-paced
QRS width
(200 vs
200 ms)
Overall OR 2.27 (1.04–4.97) . . .
P value 0.04
Ischemic OR 1.35 (0.46–3.91) 0.04
P value 0.58
Non-ischemic OR 5.12 (1.47–17.81)
P value 0.01
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chemic cardiomyopathy patients had a significantly higher
likelihood of response to both CCS and LVESV in the univari-
able, but not the multivariable, model. The reason that the cause
of cardiomyopathy was highly significant in univariable, but not
multivariable, analysis is explained by the positive correlation
between cause of cardiomyopathy and other significant ECG
parameters. To further examine the relationship between cause
of cardiomyopathy and ECG predictors, significant multivari-
able parameters for CRT response were analyzed for interaction
with cause of cardiomyopathy. Of the 4 parameters that pre-
dicted either CCS or LVESV response after multivariable
analysis, 3 had no interaction with cause of cardiomyopathy.
Only QRS bundle branch block morphological features better
predicted CCS response in patients with nonischemic cardiomy-
opathy (OR6.34, P0.01) (Table 3). None of the ECG
parameters that predicted an improvement in LVESV interacted
with cardiomyopathy cause, suggesting the ECG parameters are
applicable to both (Table 4). The dichotomized LV-paced QRS
width 200 ms interacted and was significantly more predictive
for patients with a nonischemic cause of cardiomyopathy
(OR5.12) (Table 5). Parameters that are affected by lead
position, including the difference between Bi-V and preimplan-
tation QRS width and LV-paced QRS width, appear to be
predictive for both ischemic and nonischemic cardiomyopathies.
The LV-paced QRS width represents a novel ECG parameter
not previously examined. Pacing an area of scar in the left
ventricle may not improve dyssynchrony and can lead to
nonresponse.30 LV-paced QRS width may be an indirect method
of identifying a region near scar or an area of poor conduction.
In this case, a narrower LV-paced QRS duration would suggest
electrically viable tissue and a wider LV-paced QRS would
imply proximity to a region of scar where electric signals
conduct slowly and resynchronization is less likely to occur.
Overall, we found that the narrower the LV-paced QRS width,
the more likely there will be a CRT LVESV response, with an
OR of 0.86 (P0.01). Specifically, an LV-paced QRS width of
200 ms was 2 times more likely to be associated with a
positive response than having an LV-paced QRS width 200
ms (OR2.27, P0.04). Although the nondichotomized LV-
paced QRS did not interact with cause of cardiomyopathy, the
dichotomized LV-paced QRS did interact. Once again, we found
that this parameter was most useful in patients with nonischemic
cardiomyopathy, in whom an LV-paced QRS width of 200 ms
was associated with a 5-fold increased likelihood of an
improved LVESV response to CRT (OR5.12, P0.01).
Clinical Implications
In our PROSPECT-ECG substudy, only QRS left bundle branch
morphological features were predictive of both LVESV and
CCS response; other ECG parameters were predictive of 1 or the
other. Both parameters that predicted either LVESV or CCS
response (namely, LV-paced QRS width and the difference
between Bi-V and preimplantation QRS width) can be measured
intraprocedurally and can be used by the CRT implanter to
optimize LV lead placement or pacing. To improve CRT
response, as measured by CCS or LVESV, our data suggest only
selecting patients with baseline LBBB. In addition, during CRT
implantation, particularly in patients with a nonischemic cardio-
myopathy, it is recommended that the LV lead be positioned to
minimize both the LV-paced QRS and the Bi-V–paced QRS
widths, especially if there are multiple coronary veins, multiple
locations within a vein, or multiple pacing configurations from
which to choose. This hypothesis will require further study to
determine if prospectively optimizing ECG parameters during
CRT implantation will result in an increased CRT response rate.
Limitations
First, this was an observational study that will require validation
with a future study. Second, no long-term outcome 6 months
is available. The current definition of CRT response does not
account for disease progression. Patients who are classified as
nonresponders may actually represent positive response with
attenuation of disease progression.31 Without a control group to
follow natural progression, this cannot be validated. Other
parameters relating to CRT response, including extent of myo-
cardial scar, percentage of Bi-V pacing, and adherence to
medical therapy, were not evaluated in this study. Regarding the
multivariable analyses involving the dichotomy of postimplan-
tation LV QRS width and LVESV response, the threshold value
defining the dichotomy was data derived and subjectively
chosen. Statistical methods, such as cross validation, could be
used to select a threshold in a more rigorous manner and to
investigate the robustness of the estimated effect.
Conclusions
The ECG is a simple and inexpensive tool that can help
identify candidates for CRT and guide the selection of the
optimal vein for resynchronization. In PROSPECT-ECG,
only QRS left bundle branch morphological features pre-
dicted both CCS and LVESV response; LV-paced QRS width
predicted LVESV response, and the difference between Bi-V
and preimplantation QRS widths predicted CCS response. In
addition, we present a potentially novel ECG parameter,
LV-paced QRS width, as a predictor of LVESV response.
Some ECG parameters were more predictive of CRT re-
sponse in patients with a nonischemic cardiomyopathy.
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CLINICAL PERSPECTIVE
In our PROSPECT-ECG substudy, only QRS left bundle branch block (LBBB) morphological features were predictive of
both left ventricular end systolic volume (LVESV) and clinical composite score (CCS) response; other ECG parameters
were predictive of 1 or the other. Both parameters that predicted either LVESV or CCS response (namely, LV-paced QRS
width and the difference between biventricular [Bi-V] and preimplantation QRS width) can be measured intraprocedurally
and can be used by the cardiac resynchronization therapy (CRT) implanter to optimize LV lead placement or pacing. To
improve CRT response, as measured by CCS or LVESV, our data suggest selecting only patients with baseline LBBB. In
addition, during CRT implantation, particularly in patients with nonischemic cardiomyopathy, it is recommended that the
LV lead be positioned to minimize both the LV-paced QRS and the Bi-V–paced QRS widths, especially if there are
multiple coronary veins, multiple locations within a vein, or multiple pacing configurations from which to choose.
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